ANBIO BIOTECHNOLOGY LTD (NNNN) Stock Price, Forecast & Analysis
USA - NASDAQ:NNNN - KYG0367B1059 - Common Stock
NNNN Key Statistics, Chart & Performance
The current stock price of NNNN is 27.24 USD. In the past month the price decreased by -9.77%.
NNNN Latest News, Press Relases and Analysis
NNNN Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.76 | 413.38B | ||
| AMGN | AMGEN INC | 15.62 | 183.96B | ||
| GILD | GILEAD SCIENCES INC | 15.15 | 153.97B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 25 | 111.28B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.65 | 74.65B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 903.02 | 60.37B | ||
| INSM | INSMED INC | N/A | 41.72B | ||
| NTRA | NATERA INC | N/A | 28.28B | ||
| BIIB | BIOGEN INC | 9.84 | 24.14B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.88 | 21.34B | ||
| INCY | INCYTE CORP | 16.23 | 20.34B | ||
| NBIX | NEUROCRINE BIOSCIENCES INC | 34.34 | 14.24B |
Related stock screener links
About NNNN
Company Profile
Anbio Biotechnology is a medical device company. The company is headquartered in Frankfurt, Hessen and currently employs 27 full-time employees. The company went IPO on 2025-02-19. The firm is engaged in the development of medical technology and the provision of in vitro diagnostics (IVD) products. Its products offer solutions for over the counter (OTC) use, point-of-care (POCT) settings, and laboratory applications, ensuring that both healthcare providers and patients have access to reliable and efficient diagnostic tools in any setting. Its IVD products detect a wide range of biomarkers across critical medical fields, including infectious diseases, cancer, cardiovascular diseases, inflammation, drug abuse, endocrine disorders, renal disease, pharmacogenomics, and diabetes. Some of its IVD platforms: Chemiluminescence Immunoassay (ChLIA), Lateral Flow Immunoassay (LFIA), Fluorescent Immunoassay (FIA), Polymerase Chain Reaction (PCR) and Loop-mediated Isothermal Amplification (LAMP).
Company Info
ANBIO BIOTECHNOLOGY LTD
Friedrich-Ebert-Anlage 49
Frankfurt HESSEN DE
Employees: 27
Phone: 4916096247281
ANBIO BIOTECHNOLOGY LTD / NNNN FAQ
Can you describe the business of ANBIO BIOTECHNOLOGY LTD?
Anbio Biotechnology is a medical device company. The company is headquartered in Frankfurt, Hessen and currently employs 27 full-time employees. The company went IPO on 2025-02-19. The firm is engaged in the development of medical technology and the provision of in vitro diagnostics (IVD) products. Its products offer solutions for over the counter (OTC) use, point-of-care (POCT) settings, and laboratory applications, ensuring that both healthcare providers and patients have access to reliable and efficient diagnostic tools in any setting. Its IVD products detect a wide range of biomarkers across critical medical fields, including infectious diseases, cancer, cardiovascular diseases, inflammation, drug abuse, endocrine disorders, renal disease, pharmacogenomics, and diabetes. Some of its IVD platforms: Chemiluminescence Immunoassay (ChLIA), Lateral Flow Immunoassay (LFIA), Fluorescent Immunoassay (FIA), Polymerase Chain Reaction (PCR) and Loop-mediated Isothermal Amplification (LAMP).
Can you provide the latest stock price for ANBIO BIOTECHNOLOGY LTD?
The current stock price of NNNN is 27.24 USD. The price increased by 4.69% in the last trading session.
What is the dividend status of ANBIO BIOTECHNOLOGY LTD?
NNNN does not pay a dividend.
How is the ChartMill rating for ANBIO BIOTECHNOLOGY LTD?
NNNN has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 6 out of 10.
Which stock exchange lists NNNN stock?
NNNN stock is listed on the Nasdaq exchange.
What is the outstanding short interest for ANBIO BIOTECHNOLOGY LTD?
The outstanding short interest for ANBIO BIOTECHNOLOGY LTD (NNNN) is 0.3% of its float.
NNNN Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to NNNN.
NNNN Fundamental Analysis
ChartMill assigns a fundamental rating of 6 / 10 to NNNN. Both the health and profitability get an excellent rating, making NNNN a very profitable company, without any liquidiy or solvency issues.
NNNN Financial Highlights
Over the last trailing twelve months NNNN reported a non-GAAP Earnings per Share(EPS) of 0.04. The EPS increased by 57.95% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 42.53% | ||
| ROA | 31.55% | ||
| ROE | 34.72% | ||
| Debt/Equity | 0 |